Sodium-glucose co-transporter-2 inhibitors and susceptibility to COVID-19: A population-based retrospective cohort study.
|アブストラクト||Sodium-glucose co-transporter-2 (SGLT2) inhibitors are widely prescribed in people with type 2 diabetes. We aimed to investigate whether SGLT2 inhibitor prescription is associated with COVID-19, when compared with an active comparator. We performed a propensity-score-matched cohort study with active comparators and a negative control outcome in a large UK-based primary care dataset. Participants prescribed SGLT2 inhibitors (n = 9948) and a comparator group prescribed dipeptidyl peptidase-4 (DPP-4) inhibitors (n = 14 917) were followed up from January 30 to July 27, 2020. The primary outcome was confirmed or clinically suspected COVID-19. The incidence rate of COVID-19 was 19.7/1000 person-years among users of SGLT2 inhibitors and 24.7/1000 person-years among propensity-score-matched users of DPP-4 inhibitors. The adjusted hazard ratio was 0.92 (95% confidence interval 0.66 to 1.29), and there was no evidence of residual confounding in the negative control analysis. We did not observe an increased risk of COVID-19 in primary care amongst those prescribed SGLT2 inhibitors compared to DPP-4 inhibitors, suggesting that clinicians may safely use these agents in the everyday care of people with type 2 diabetes during the COVID-19 pandemic.|
|ジャーナル名||Diabetes, obesity & metabolism|
|投稿者||Sainsbury, Christopher; Wang, Jingya; Gokhale, Krishna; Acosta-Mena, Dionisio; Dhalla, Samir; Byne, Nathan; Chandan, Joht Singh; Anand, Astha; Cooper, Jennifer; Okoth, Kelvin; Subramanian, Anuradhaa; Bangash, Mansoor N; Taverner, Thomas; Hanif, Wasim; Ghosh, Sandip; Narendran, Parth; Cheng, Kar K; Marshall, Tom; Gkoutos, Georgios; Toulis, Konstantinos; Thomas, Neil; Tahrani, Abd; Adderley, Nicola J; Haroon, Shamil; Nirantharakumar, Krishnarajah|
|組織名||Institute of Applied Health Research, University of Birmingham, Birmingham, UK.;Department of Diabetes, Gartnavel General Hospital, NHS Greater Glasgow and;Clyde, Glasgow, UK.;Cegedim Health Data, Cegedim Rx, London, UK.;The Health Improvement Network (THIN), London, UK.;Institute of Clinical Sciences, University of Birmingham, Birmingham, UK.;Department of Critical Care, University Hospitals Birmingham NHS Foundation;Trust, Birmingham, UK.;Institute of Metabolism and Systems Research, University of Birmingham,;Birmingham, UK.;Institute of Cancer and Genomic Sciences, University of Birmingham, Birmingham,;UK.;Department of Diabetes and Endocrinology, University Hospitals Birmingham NHS;Foundation Trust, Birmingham, UK.;Midlands Health Data Research UK, Birmingham, UK.|